Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott Gettinger, David C. Smith, David F. McDermott, John D. Powderly, Richard D. Carvajal, Jeffrey A. Sosman, Michael B. Atkins, Philip D. Leming, David R. Spigel, Scott Antonia, Leora Horn, Charles G. Drake, Drew M. Pardoll, Lieping Chen, William H. Sharfman, Robert A. Anders, Janis M. Taube, Tracee L. McMiller, Haiying Xu, Alan J. Korman, Maria Jure–Kunkel, Shruti Agrawal, D. G. McDonald, Georgia Kollia, Ashok Gupta, Jon M. Wigginton, Mario Sznol

New England Journal of Medicine, 2012

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Dana-Farber Cancer Institute, Yale Cancer Center, Yale University, University of Michigan–Ann Arbor, Hadassah Medical Center, Carolina BioOncology Institute, Memorial Sloan Kettering Cancer Center, Vanderbilt University Medical Center, Oncology Hematology Care, Sarah Cannon, Tennessee Oncology, Moffitt Cancer Center, Bristol-Myers Squibb (United States)

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

12558

Citations

View on Google Scholar

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Abstract

Journal Details

Join JournalsHub

Welcome Back